Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology ·Vol. 19 ·No. 3 ·2008-03-00 ·Pages 595-7

Cottu PH, Asselah J, Lae M, Pierga JY, Diéras V, Mignot L, Sigal-Zafrani B, Vincent-Salomon A

Abstract

暂无摘要

MeSH Terms

Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols/therapeutic use Breast Neoplasms/genetics,therapy Capecitabine Carcinoma, Ductal/genetics,secondary,therapy Combined Modality Therapy Deoxycytidine/administration & dosage,analogs & derivatives Docetaxel Female Fluorouracil/administration & dosage,analogs & derivatives Genes, erbB-2/genetics Humans Liver Neoplasms/genetics,secondary Middle Aged Remission Induction Taxoids/administration & dosage Trastuzumab

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Taxoids Deoxycytidine Docetaxel Capecitabine Trastuzumab Fluorouracil

Authors & Affiliations

8 authors, click to expand affiliations / ORCID

Cottu P H

Asselah J

Lae M

Pierga J-Y

Diéras V

Mignot L

Sigal-Zafrani B

Vincent-Salomon A

Article Info

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Abbr.

Ann Oncol

ISSN

1569-8041

DOI

10.1093/annonc/mdn021

Published

2008-03-00

Epub

2008-00-13

Pages

595-7

Language

English

Region

England

NLM ID

9007735

Subset

External Links

PubMed source DOI: 10.1093/annonc/mdn021 View journal details

Analysis Services

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer.

Contact

WeChat Official Account